Molecular Formula | C22H13FN2O5 |
Molar Mass | 404.35 |
Solubility | DMSO : 250 mg/mL (618.28 mM; Need ultrasonic) |
Storage Condition | -20℃ |
Use | 9-ING-41 is a potent glycogen synthase kinase 3 (GSK-3) inhibitor. 9-ING-41 induces prophase apoptosis and cell cycle arrest by targeting centrosome and microtubule-bound GSK-3β. 9-ING-41 has anti-tumor activity. |
Target | GSK-3β |
In vitro study | 9-ING-41 is a clinically relevant small-molecule GSK-3β inhibitor with a broad spectrum of preclinical antitumor activity, which can inhibit the growth of neuroblastoma cells. |
In vivo study | 9-ING-41 has single-agent antitumor activity in the MCL mouse model. Mouse xenograft studies have shown that the combination of CPT-11 and 9-ING-41 at clinically relevant doses can produce a greater antitumor effect than either drug alone. |
Reference Show more | 1: Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ. GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017 Nov 11;8(70):114924-114934. doi: 10.18632/oncotarget.22414. eCollection 2017 Dec 29. PubMed PMID: 29383130; PubMed Central PMCID: PMC5777742. 2: Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30. PubMed PMID: 28672195; PubMed Central PMCID: PMC5496477. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.473 ml | 12.366 ml | 24.731 ml |
5 mM | 0.495 ml | 2.473 ml | 4.946 ml |
10 mM | 0.247 ml | 1.237 ml | 2.473 ml |
5 mM | 0.049 ml | 0.247 ml | 0.495 ml |
use | 9-ING-41 is an effective inhibitor of glycogen synthase kinase 3(GSK-3) and has anti-tumor activity. 9-ING-41 induces prophase apoptosis and cell cycle arrest by targeting centrosome and binding microtubule GSK3β. |
in vivo study | 9-ING-41 has mono-drug antitumor activity in MCL mouse models. Mouse xenograft studies have shown that a combination of clinically relevant doses of CPT-11 and 9-ING-41 produces a greater antitumor effect than either drug alone. |
in vitro study | 9-ING-41 is a clinically relevant small molecule GSK-3β inhibitor with broad-spectrum preclinical anti-tumor activity and can inhibit the growth of neuroblastoma cells. |
biological activity | 9-ING-41 is an effective inhibitor of glycogen synthase kinase-3 (GSK-3) and has anti-tumor activity. 9-ING-41 induces apoptosis and cell cycle arrest in the prophase of cell division by targeting centrosome and binding to microtubule GSK3β. |
target | TargetValue GSK-3 () |
Target | Value |